# Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

> **NCT06931340** · PHASE3 · RECRUITING · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 1260 (estimated)

## Conditions studied

- Castration-Sensitive Prostate Carcinoma
- Metastatic Prostate Adenocarcinoma
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **DRUG:** Androgen Therapy
- **DRUG:** Apalutamide
- **DRUG:** Docetaxel
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Bone Scan
- **PROCEDURE:** PSMA PET Scan
- **PROCEDURE:** Biospecimen Collection
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT06931340
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2031-11-11
- **Final completion:** 2039-05-08
- **Target enrollment:** 1260 (ESTIMATED)
- **Last updated:** 2026-05-08

## Collaborators

- National Cancer Institute (NCI)

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06931340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06931340, "Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT06931340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*